Day: June 27, 2025

Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will present at the following investor conferences: mwb online Health Care ConferenceDate: July 1, 2025Presentation Time: 12:00 pm CEST Attendees: Frank Weber, CEO; Julia Neugebauer, COOVirtual conferenceLink to conference https://research-hub.de/events/registration/2025-07-01-12-00/VVY-NA H.C. Wainwright 4th Annual Kidney Virtual ConferenceDate: July 14, 2025 Presentation Time: 3:00 pm CEST / 9:00 am EDTAttendees: Frank Weber, CEO; Julia Neugebauer, COOVirtual...

Press Release dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 27, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital. This share repurchase program started for an initial €500 million and will now be increased to €1 billion, following the completion of the previously announced sale of dsm-firmenich’s stake in the Feed Enzymes Alliance. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total amount of €580 million, of which €80 million to cover commitments under the Group’s share-based compensation plans and €500 million to reduce its issued...

SIKA ACQUIRES RENOWNED CONSTRUCTION CHEMICALS COMPANY IN QATAR Sika has acquired Gulf Additive Factory LLC in the State of Qatar. The company manufactures a wide range of construction chemical products and has a strong standing in the fast-growing Qatar construction market. The acquisition strengthens Sika’s foothold in the country and provides exciting opportunities for further expansion. Gulf Additive Factory LLC (GAF) is renowned for its high-quality solutions and profound technical expertise. An extensive product range, including concrete admixtures, mortars, flooring, waterproofing and facade systems (EIFS: Exterior Insulation and Finish System) is manufactured in a strategically well-located production facility close to Doha. GAF’s large, modern manufacturing site will provide Sika with the opportunity to expand and drive growth...

The Supervisory Board of AS Harju Elekter Group decided to increase the share capital of the company by 17,010 euros by issuing new ordinary shares. The increase in the share capital is due to the need to issue new shares to the management board members and key personnel of Harju Elekter and its subsidiaries participating in the option program approved with the resolution of the general meeting on 29 April 2021. A total of 4 current and former employees of Harju Elekter participated in the share issue related to the implementation of the option program, who subscribed for a total of 27,000 shares for a total of 121,500 euros.  A total of 57,500 shares were not subscribed. Decisions of the Supervisory Board of AS Harju Elekter Group:Harju Elekter’s share capital will be increased by a maximum of 17,010 euros, i.e., from 11,654,225.10...

TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) — Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for Yesafili™ (aflibercept), a biosimilar to Eylea® (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL on June 26, 2025. This approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada. YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of:Neovascular (wet) age-related macular degeneration (AMD) Visual impairment due to macular edema secondary...

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $44.00 per share and the pre-funded warrants are being sold at a public offering price of $43.9999 per pre-funded warrant, which represents...

SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common stock and accompanying common warrants were offered collectively at a price to the public of $3.00 per share and accompanying common warrant. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock and/or accompanying common warrants to purchase up to an additional...

Ruling provides clarity on the future of master planned Los Angeles County community TEJON RANCH, Calif., June 26, 2025 (GLOBE NEWSWIRE) — Tejon Ranch Co. (NYSE:TRC), (“Tejon” or the “Company”), a diversified real estate development and agribusiness company, today released the following statement in response to the California Court of Appeals’ decision to uphold the Los Angeles County Superior Court’s previous decision regarding the Company’s Centennial development. We disagree with the Court of Appeals’ ruling and importantly note that the decision affirms that the Company prevailed on 20 of the 23 items resolved at the trial court. Furthermore, the ruling does not address any additional issues. In the coming days, we intend to work with Los Angeles County to evaluate how best to advance Centennial in a way that benefits the region...

CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) — Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), is pleased to announce it has entered into an agreement (the “Marwayne Agreement”) with O’Neill Industries International-Canada Inc. (“O’Neill Canada”) that will result in the transfer of certain wells and other assets located in Marwayne, Alberta, related liabilities, licenses and leases from Acceleware to O’Neill Canada, and the termination of the existing farmout and option agreement dated May 19, 2020 between the Company and O’Neill Canada. O’Neill Canada is the Canadian entity of O’Neill Industries, a US based company active in upstream production and oil field services globally. In exchange for the above noted transfers, Acceleware will receive cash payments and a gross overriding royalty (“GORR”) on future production...

Settlement of Tranche 1 of the Placement for A$18.2m TORONTO and PERTH, Australia, June 26, 2025 (GLOBE NEWSWIRE) — Further to the ASX announcement on 20 June 2025, Cygnus Metals Limited (“Cygnus” or the “Company”) advises that it has issued a total of 211,627,907 fully paid ordinary shares (“Shares”) at A$0.086 each under Tranche 1 of the Placement, raising a total of A$18,200,000 (before costs). The Shares were issued under the Company’s existing capacity under ASX Listing Rules 7.1 (126,702,591) and 7.1A (84,925,316). A further 1,162,790 Shares are intended to be issued under Tranche 2 of the Placement to Non-Executive Director Raymond Shorrocks, or his nominees, subject to receipt of shareholder approval at a general meeting to be held in August 2025. In addition, the Company has issued a total of 306,129 Shares to employees...